Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krsnaa DiagnosticsBOM:543328 -1.86%63 Pretax Margin % is 26.84% as of Mar. 2026, which is 74% above its 10-year median of 15.39. GuruFocus rates BOM:543328 with a GF Score™ of 63/100 and a GF Value™ of ₹924.39 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Krsnaa Diagnostics ranks better than 85.07% on this metric.
The historical rank and industry rank for Krsnaa Diagnostics's Pretax Margin % or its related term are showing as below:
BOM:543328'
s Pretax Margin % Range Over the Past 10 Years
Min: -61.27 Med: 15.39 Max: 74.52
Current: 16.87
BOM:543328's Pretax Margin % is ranked better than 85.07% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.57
vs BOM:543328: 16.87
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Krsnaa Diagnostics Pretax Margin % Related Terms
Krsnaa Diagnostics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Krsnaa Diagnostics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543328 vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Krsnaa Diagnostics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krsnaa Diagnostics Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Krsnaa Diagnostics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Krsnaa Diagnostics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krsnaa Diagnostics (BOM:543328) has a Pretax Margin % of 26.84% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Krsnaa Diagnostics and its competitors. This is 74% above median its historical median of 15.39. According to the industry distribution chart, Krsnaa Diagnostics ranks #30 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 14.9%.
Is Krsnaa Diagnostics' Pretax Margin % too high?
Krsnaa Diagnostics' current Pretax Margin % of 26.84% is 74% above median its 10-year median of 15.39. Based on the distribution chart, Krsnaa Diagnostics ranks #30 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Krsnaa Diagnostics has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Krsnaa Diagnostics' Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Krsnaa Diagnostics ranks #30 out of 201 companies for Pretax Margin %. This places Krsnaa Diagnostics in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Krsnaa Diagnostics and its competitors. Krsnaa Diagnostics's current Pretax Margin % is 26.84%, which is 74% above median its own 10-year median of 15.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krsnaa Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Krsnaa Diagnostics (BOM:543328) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹924.39, compared to a current price of ₹523.95 — trading 43.3% below its estimated fair value. The current Pretax Margin % is 26.84%, which is 74% above median its 10-year median of 15.39. Krsnaa Diagnostics' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Krsnaa Diagnostics (BOM:543328), the current Pretax Margin % is 26.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krsnaa Diagnostics (BOM:543328) Overvalued in 2026?
Based on GuruFocus' analysis, Krsnaa Diagnostics stock appears to be undervalued.
The current stock price of ₹523.95 is trading 43.3% below its estimated GF Value™ of ₹924.39.
GuruFocus considers Krsnaa Diagnostics to be Significantly Undervalued.
Key valuation signals for BOM:543328:
Pretax Margin %: 26.84% (74% above median its 10-year median of 15.39)
GF Value™: ₹924.39 vs. price of ₹523.95 (43.3% below fair value)
No single metric tells the full story. See the BOM:543328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krsnaa Diagnostics Ltd is a diagnostic services provider, both in Radiology and Pathology. It offers a wide range of diagnostic services such as imaging/radiology services, routine clinical laboratory tests, pathology, and tele-radiology services to private and public hospitals, medical colleges, and community health centres. The company's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, tele-reporting services, and all types of Blood and Urine investigations.
63GF Score
Get the complete analysis for BOM:543328
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543328 has been successfully added to your 
